Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus

G. Robuschi, L. d’Amato, M. Salvi, E. Gardini, M. Montermini, E. Dall’Aglio, E. Borciani, V. Fontanesi, A. Alboni, A. Gnudi, Elio Roti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.

Original languageEnglish
Pages (from-to)521-524
Number of pages4
JournalJournal of Endocrinological Investigation
Volume7
Issue number5
DOIs
Publication statusPublished - 1984

Fingerprint

Thyrotropin-Releasing Hormone
Somatostatin
Prolactin
Fetus
Fetal Blood
Newborn Infant
Pregnant Women
Mothers
Pituitary Hormones
Parturition
Peptides

Keywords

  • fetus
  • PRL
  • SRIF
  • TRH

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus. / Robuschi, G.; d’Amato, L.; Salvi, M.; Gardini, E.; Montermini, M.; Dall’Aglio, E.; Borciani, E.; Fontanesi, V.; Alboni, A.; Gnudi, A.; Roti, Elio.

In: Journal of Endocrinological Investigation, Vol. 7, No. 5, 1984, p. 521-524.

Research output: Contribution to journalArticle

Robuschi, G, d’Amato, L, Salvi, M, Gardini, E, Montermini, M, Dall’Aglio, E, Borciani, E, Fontanesi, V, Alboni, A, Gnudi, A & Roti, E 1984, 'Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus', Journal of Endocrinological Investigation, vol. 7, no. 5, pp. 521-524. https://doi.org/10.1007/BF03348461
Robuschi, G. ; d’Amato, L. ; Salvi, M. ; Gardini, E. ; Montermini, M. ; Dall’Aglio, E. ; Borciani, E. ; Fontanesi, V. ; Alboni, A. ; Gnudi, A. ; Roti, Elio. / Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus. In: Journal of Endocrinological Investigation. 1984 ; Vol. 7, No. 5. pp. 521-524.
@article{a136afc370694baaa40672f07a7cc339,
title = "Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus",
abstract = "To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.",
keywords = "fetus, PRL, SRIF, TRH",
author = "G. Robuschi and L. d’Amato and M. Salvi and E. Gardini and M. Montermini and E. Dall’Aglio and E. Borciani and V. Fontanesi and A. Alboni and A. Gnudi and Elio Roti",
year = "1984",
doi = "10.1007/BF03348461",
language = "English",
volume = "7",
pages = "521--524",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "5",

}

TY - JOUR

T1 - Absent prolactin (PRL) response to thyrotropin releasing hormone (TRH) and somatostatin (SRIF) in at term fetus

AU - Robuschi, G.

AU - d’Amato, L.

AU - Salvi, M.

AU - Gardini, E.

AU - Montermini, M.

AU - Dall’Aglio, E.

AU - Borciani, E.

AU - Fontanesi, V.

AU - Alboni, A.

AU - Gnudi, A.

AU - Roti, Elio

PY - 1984

Y1 - 1984

N2 - To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.

AB - To study the effect of thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) on prolactin (PRL) secretion in at term human fetus these peptides have been administered to at term pregnant women during labor. Evidence has been reported that TRH and SRIF cross the placental barrier and affect the secretion of pituitary hormones. 400 μg TRH were administered to 37 pregnant women. As control 11 women received saline. In cord blood (CB) of neonates whose mothers received TRH CB PRL concentration was not different from those treated with saline, with values ranging between 192 ± 18 and 342 ± 48 ng/ml. 500 μg cyclic SRIF diluted in saline was infused over a period of 30 min in 55 women. Control subjects were infused with saline. At birth CB PRL concentration in SRIF treated neonates ranged between 266 ± 32 and 327 ± 48 ng/ml. In neonates whose mothers were treated with saline, CB PRL was 305 ± 31 ng/ml. This value was not significantly different from that in SRI F-treated groups. Our findings suggest that in at term human fetus TRH does not stimulate PRL secretion probably because fetal pituitary secretes PRL at maximal releasing activity. Furthermore SRIF administration does not have any effect on fetal PRL secretion as consistently observed in adults.

KW - fetus

KW - PRL

KW - SRIF

KW - TRH

UR - http://www.scopus.com/inward/record.url?scp=0021714916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021714916&partnerID=8YFLogxK

U2 - 10.1007/BF03348461

DO - 10.1007/BF03348461

M3 - Article

VL - 7

SP - 521

EP - 524

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 5

ER -